about
Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterizationNon-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the LiteratureNondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer.MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study.Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial.Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. Feasibility, toxicity and long-term results of a phase II study.Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey.Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience.Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens.Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer.The surgeon and the oncologist in non-small cell lung cancer (NSCLC).Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment.Effects of sulfonylureas on tumor growth: a review of the literature.Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer.An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma.Treatment of Unfit Patients With Advanced Non-Small-Cell Lung Cancer: Definition Criteria According an Expert Panel.Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment.HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer.A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma.LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab.Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.A pathological complete response after preoperative chemotherapy with carboplatin and pemetrexed in malignant pleural mesothelioma: A case reportAdvanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.Effect of induction chemotherapy on lung function and exercise capacity in patients affected by malignant pleural mesothelioma.Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease.Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma PThe predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.Preoperative concomitant chemo-radiotherapy in superior sulcus tumour: A mono-institutional experience.Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the eldPemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study.
P50
Q26765060-0DA3F618-9B73-4394-B398-7373785E0697Q26777427-6622B0C9-D1F5-4538-A824-3CB36393BE0CQ30360938-55BAD2AE-2B0A-4896-B886-24F1E323A2CAQ31019143-4CE73622-A16E-425E-847E-7BCD7E1E289DQ33337168-EE0DF1C8-FDB3-4BD4-A786-78E761ED1900Q33348171-F8022208-FFD9-4374-AEFE-64F534285C56Q33370117-ED763ABB-AC80-4AC4-B2C0-803508248063Q33374747-08721F53-1E8E-4545-8DDA-B6855C7869DDQ33374797-730F9F8B-E89B-4892-8CFC-0E99D2D2BC0EQ33379936-E34AC5EC-A10F-410D-A02E-B167D00B0A0FQ33394000-6CCA5D15-B865-467F-924E-575F97A025B3Q33498336-E3C96AF3-B92E-4378-BE24-54089002B44FQ33779181-395253A3-9265-4A3D-9AE0-6B2A48CB9265Q33918135-B4C658F9-2BBC-4EB3-9DD5-068A7C4087F9Q34402081-9016628C-AD8F-4C1D-B375-3298428EB311Q35872199-A92A3F59-0A5C-45EB-B8F9-6D553D349224Q36017990-7172661A-D9B2-4B59-9804-C0BEB7064911Q36522796-429A7037-7C48-4BDD-AE65-44F612097856Q37042501-638E9190-BC75-4339-9E7B-105FFC3E826BQ37247194-140F4651-90BD-4650-BCFD-04B1E6B4F555Q37858556-951A5097-B60F-4FCA-AA4F-22CEC81FFA97Q37998200-1B191FE5-6CA5-4553-B3FB-813FFC7CDAD0Q38491810-C63DBC7A-C09E-4788-8087-D5AFD70082FBQ38584437-6442F309-0249-4164-A72A-7FBE421AA8B2Q38707311-BEF8ADA2-AB30-450E-A186-282DBC1994DFQ38720451-0F5726AC-FDC8-4082-AA74-8BD4C40031B1Q38985572-5C01210E-A479-4E84-BD1A-54511DDF28B0Q39001187-08E95E5F-86F2-4D29-AC1A-6A025BBA89B7Q40251565-311D22CE-8C94-4087-8282-3FA060F0147CQ40340826-A4C58260-2FEE-4B40-947E-F146310477A0Q42214080-2380CE02-6242-4205-B2FA-E94BBE4C4A40Q43163001-A19694A6-30AE-4E83-9AF4-8DEC6306DDBEQ44874525-5CC39431-DC48-49EC-BAD1-0C2C25CC28AAQ44886865-CB81D12A-0FF2-47AE-B1DB-4D8F771D75C1Q45043016-FB7DE359-2F28-488D-89B5-EDD22A845697Q45230559-83242E2C-4974-4A5E-BD79-96640B1C849AQ45347866-BA35C4D3-07FC-44FD-8C7A-07BAE0312EF2Q45920073-60B1FEDA-885E-4136-949F-14F05C8CB5BFQ46726889-418EE7E7-E90D-4A53-8752-4EEBB2CB2DC9Q46893703-35E565F2-6A78-4B11-A15F-B32278F70AF3
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Adolfo Favaretto
@ast
Adolfo Favaretto
@en
Adolfo Favaretto
@es
type
label
Adolfo Favaretto
@ast
Adolfo Favaretto
@en
Adolfo Favaretto
@es
prefLabel
Adolfo Favaretto
@ast
Adolfo Favaretto
@en
Adolfo Favaretto
@es
P106
P21
P214
6784155566443313380006
P31
P496
0000-0001-8175-7467
P735
P7859
viaf-6784155566443313380006